Wednesday, March 31, 2010

CAPA Basics - Carl Anderson and Barbara Immel

I always enjoy running across well-written GXP articles.  Kudos to Carl for posting this informative CAPA Basics article by Barbara Immel on his blog (GXP Perspectives), CAPA Basics- Corrective And Preventative Action.

I've been following Barbara Immel's writing for some time, and always pick up several pearls of wisdom from her.

Return Home: The Health, Drug, Prescription, and GMP Supersite Blog

You might also be interested in:

Root Cause Analysis & Deviation Investigation Report Writing - An online self-study course - FDA, cGMP, QSR, GMP Training

SkillsPlus Intl Inc. - The best GMP training, best QSR training, best instructors
SkillsPlus Intl Info Blog

Monday, March 29, 2010

Biosimilars In Recently Passed Healthcare Bill

I was really surprised to find out that biosimilars are included in the recently passed healthcare bill, Patient Protection and Affordable Care Act.  I learned about this while reading Kevin O'Donnell's post on his blog (Where cooler heads prevail), "New U.S. Healthcare Bill Includes Pathway for Biosimilars and 12 Year Patent Exclusivity."

Kevin writes:

"This provision, Title VII- Providing Access to Innovative Medical Therapies, "prohibits the approval of an application as either biosimilar or interchangeable until 12 years from the date on which the reference product is first approved. In addition, it stipulates an additional 6 months of exclusivity for the use of reference products "in the pediatric population.""
References:
Full text of the Patient Protection and Affordable Care Act HR 3590

Return Home: http://drughealth.blogspot.com/

Saturday, March 27, 2010

FDA Controversy - Regen Biologic's Menaflex Device

The FDA is reassessing the safety of a device (Regen Biologic's Menaflex Device) that it previously approved for patients. The FDA conducted a March 23, 2010: Orthopaedic and Rehabilitation Devices Panel Meeting. Although the panel expressed that they would have liked to have seen more data on the device, they largely backed it as a safe and effective therapy.

The larger looming issue now is whether this will become precendent setting and raise the prospect of FDA re-evaluating previously approved devices.

Return Home: http://drughealth.blogspot.com/

Wednesday, March 24, 2010

FDA Webinar on FDA Inspection Process


When:     Thursday, March 25, 2010, at 2 p.m. ET

Where:    https://collaboration.fda.gov/inspectionprocess/

Host:       FDA’s Office of Regulatory Affairs (ORA), 301-827-3101

             ORAContactUs@FDA.HHS.GOV

Speaker: Michael C. Rogers, deputy director, Office of Regional Operations

To ensure the safety of marketed products, FDA experts inspect domestic and foreign establishments, check shipments of imported products, and collect and test product samples for signs of contamination.

During this webinar, FDA experts will present information on

  • the organization within FDA that is charged with conducting inspections
  • the facilities FDA is responsible for inspecting
  • what an inspection involves
  • inspection follow-up and enforcement actions
  • the rigorous training that inspectors receive
The presentation will run approximately 30 minutes and will include an opportunity to ask questions.

To join the webinar:

  1. Click https://collaboration.fda.gov/inspectionprocess/ (or cut and paste it into your Internet browser)
  2. Click "Enter as a Guest," fill in your name, then click "Enter Room"
  3. Dial 1-877-685-5350 and enter participant passcode: 969082
You might also be interested in:

Surviving an FDA Inspection - a training course by SkillsPlus International Inc.
This class prepares plant personnel to participate in an FDA Inspection.
Return Home: The Health, Drug, Prescription, and GMP Supersite Blog
SkillsPlus Intl Inc. - GMP Compliance Training Experts
SkillsPlus Intl Info Blog
The Health, Drug, Prescription, and GMP Supersite Gift Store 

Monday, March 22, 2010

New - FDA Orange Book

Updated May 26, 2022

The original link broke. You might also be interested in:

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations - a webpage

---  the original post follows below  ---

It's here! The February 2010 supplement of the FDA's Orange Book, APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS - 30th EDITION - Cumulative Supplement 02 - February 2010 (pdf).

Return Home: The Health, Drug, Prescription, and GMP Supersite Blog

SkillsPlus Intl Inc. - GMP and QSR Compliance Training Experts
SkillsPlus Intl Info Blog
The Health, Drug, Prescription, and GMP Supersite Gift Store 

From SkillsPlus International Inc.